Media Thread, page-10074

You note We don't really know what's going on behind the scenes @Bathurst

As a relatively new shareholder of IMU I wish you all the best. The company has perhaps a brighter future than any ASX listed stock IMO. Brilliant scientific minds and game changing technology set to revolutionaries the way cancer patients are treated for years to come. I'd be buying too if I was you.

But as far as your comment of not knowing what's going on behind the scenes, get used to it, that's par for the course at Imugene, and the very reason you are able to purchase IMU on market at such amazing prices. If Imugene's management were better at communicating, financing their future and marketing their game changing technology, you'd be paying well over $1 for the stock, as well you should. Given existing clinical trial results and the market within which they are positioned, the stock is so far undervalued IMO there's no such word for the re-rating set to occur when Vaxinia reaches its finale...

DYOR Seek investment advice as and when required Opinions only